Melatonin
Melatonin is an indoleamine best known as a regulator of circadian rhythms and sleep-wake timing, but it is also studied as a pleiotropic bioactive molecule with antioxidant, anti-inflammatory, and mitochondria-modulating properties.
Melatonin is an indoleamine best known as a regulator of circadian rhythms and sleep-wake timing, but it is also studied as a pleiotropic bioactive molecule with antioxidant, anti-inflammatory, and mitochondria-modulating properties. In biomedical research, it is frequently discussed as a therapeutic candidate rather than only as an endogenous hormone, particularly in contexts where oxidative stress, inflammation, metabolic dysfunction, and mitochondrial injury contribute to disease.
Recent work has examined melatonin across a broad range of conditions, including type 2 diabetes, polycystic ovary syndrome, osteoporosis, pulmonary arterial hypertension, metabolic syndrome-associated tissue injury, Parkinson’s disease-related biomarker patterns, and age-related ovarian and stem-cell dysfunction. Mechanistically, these studies place melatonin in pathways involving Sirtuin 1 (SIRT1), Nrf2, mitophagy, mitochondrial fission, RANKL/OPG signaling, and inflammatory mediators such as Interleukin-6 (IL-6) and tumour necrosis factor-α. It has also been considered alongside other agents such as quercetin, resveratrol, sirolimus, cholecalciferol, ubidecarenone, and insulin therapy in translational and preclinical settings.
Where the papers sit
21 papers from the last 6 months study melatonin directly · updated from PubMed 16 Nov 2026
Study type 4 clinical trials · 1 human data · 16 preclinical
Themes one subject · 1 paradigm shift · 1 new direction
Those 21 are all about one subject.
-
Melatonin Therapeutic Effects
Protective and symptom-improving effects are being explored across cancer, neurodegeneration, metabolic injury, pain, wound healing and sleep disorders. Mechanisms recur around oxidative stress, ferroptosis, PANoptosis, mitochondrial dysfunction, inflammatory signaling and macrophage or astrocyte activity. Formulations increasingly combine melatonin with nanoparticles, exosomes, hydrogels or VEGF delivery, while clinical protocols test adjunctive use for sleep, insomnia and ADHD. Evidence remains largely preclinical and heterogeneous, leaving disease-specific efficacy and dosing unresolved.
Melatonin is not uniformly benign or physiologically neutral across doses and biological systems
The randomized crossover trial in healthy adults and the pilocarpine-induced seizure-like model in zebrafish larvae both challenge the set’s prevailing treatment of melatonin as a broadly safe therapeutic agent. In adults, melatonin worsened glucose tolerance, reduced first-phase insulin secretion, and impaired insulin feedback inhibition, with effects examined in relation to the MTNR1B diabetes-risk variant; in larvae, lower concentrations reduced seizure-like responses but higher concentrations altered spontaneous contractions and increased embryonic heart rate despite no mortality or hatching effects. Together, these findings replace a simple benefit-and-safety framing with a dose- and context-dependent account in which melatonin can also disrupt metabolic or physiological function. 42346809Jun 42493757Jul
Melatonin is identified as a regulator of melanoma purinergic signaling
The human melanoma cell-line study places pharmacological melatonin in a role not otherwise used in the set: a modulator of extracellular nucleotide metabolism and the CD39/CD73 ectonucleotidase system, alongside mitochondrial depolarization and lineage-dependent transcriptional responses in SK-MEL-28 and A375 cells 42900413Oct. This extends melatonin beyond the set’s circadian, antioxidant, anti-inflammatory, neuroprotective, and tissue-repair roles by making tumor-cell purinergic signaling a direct mechanistic target.
Papers
The 21 papers from the last 6 months that study melatonin directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Melatonin Therapeutic Effects (21)
- Protective effects of melatonin against bisphenol A-mediated endometrial tumorigenesis: An experimental study targeting COX-2-dependent MMP-9 expression. Taiwanese journal of obstetrics & gynecology · 28 Oct 2026 PMID 42951462
- Melatonin suppresses astrocyte reactivity and Mitigates cognitive deficits induced by a high-carbohydrate, high-fat diet in rats. Molecular biology reports · 26 Oct 2026 PMID 42932041
- Pharmacological melatonin induces mitochondrial dysfunction and alters extracellular nucleotide metabolism and CD39/CD73 expression in human melanoma cells. Purinergic signalling · 20 Oct 2026 PMID 42900413
- Melatonin to improve sleep in patients undergoing major surgery: protocol for a double-blind, randomised placebo-controlled trial (MELROSE). BMJ open · 29 Sept 2026 PMID 42810800
- Melatonin ameliorates diabetic retinopathy by inhibiting PANoptosis via the LncSNHG5/miR-26a-5p/Hippo signaling axis. Journal of pharmacological sciences · 29 Sept 2026 PMID 42810779
- Melatonin-loaded nanoparticles reduce cisplatin-induced oxidative stress and lymphopenia: An experimental study in rats. Biochemical and biophysical research communications · 12 Sept 2026 PMID 42731366
- Melatonin@Exosome hydrogel composed of chitosan and hyaluronic acid: A promising dressing for wound healing based on exosome therapy. International journal of pharmaceutics · 7 Sept 2026 PMID 42705560
- Melatonin attenuates ferroptosis-associated injury through modulation of the thioredoxin-interacting protein/thioredoxin-1/glutathione peroxidase 4 pathway after neonatal hypoxic ischemic brain damage. Neuroreport · 3 Sept 2026 PMID 42689393
- Implementation and real-world effectiveness of a weighted blanket intervention and standard melatonin treatment for children with ADHD and sleep problems: protocol for a pragmatic longitudinal cohort study. BMC psychiatry · 26 Aug 2026 PMID 42642740
- MELODY trial: study protocol for a 12-week randomised controlled trial of adjunctive melatonin, digital cognitive behavioural therapy for insomnia or pill placebo to improve depressive symptoms in young adults with mood disorders. BMJ open · 24 Aug 2026 PMID 42637255
- A gelatin methacryloyl (GelMA)-based biomimetic melatonin/vascular endothelial growth factor-encoding plasmid (pVEGF) nerve conduit regulates the early redox-angiogenic microenvironment for long-gap peripheral nerve repair. International journal of biological macromolecules · 22 Aug 2026 PMID 42632501
- Oral administration of melatonin modulates macrophage polarization via modulating the Vegf signaling pathway and ameliorates Alzheimer's disease in APP/PS1 mice. Brain research bulletin · 17 Aug 2026 PMID 42607896
- Melatonin Ameliorates Neuropathic Pain in Mice by Regulating Pyroptosis Through Gut Microbiota-Mediated Linoleic Acid. Molecular neurobiology · 15 Aug 2026 PMID 42603252
- Multifunctional dual drug-loaded Gel-Alg/MINO/MEL composite hydrogel for combating three-dimensional multi-species biofilm and experimental periodontitis treatment. Clinical oral investigations · 6 Aug 2026 PMID 42560526
- Melatonin Modulates Behavioral and Physiological Responses in a Concentration-dependent Manner in a Pilocarpine-induced Seizure-like Model Using Zebrafish Larvae. Neurotoxicity research · 23 Jul 2026 PMID 42493757
- The protective role of melatonin on the brain in a rat model of Alzheimer's disease. Metabolic brain disease · 1 Jul 2026 PMID 42384283
- Melatonin Impairs Glucose Tolerance, First-Phase Insulin Secretion, and Insulin Feedback Inhibition; Interaction With MTNR1B Diabetes Risk Variant. Diabetes care · 25 Jun 2026 PMID 42346809
- Oxidative degradation of melatonin in solution and solid-state pharmaceutical blends: HPLC-HRMS/MS degradant characterization, metal-mediated acceleration and EDTA mitigation. Journal of pharmaceutical and biomedical analysis · 24 Jun 2026 PMID 42341649
- Dissolving Microneedles for Transdermal Delivery of Melatonin: Fabrication, Characterization, and In Vivo Pharmacokinetic Evaluation in Mice. ACS applied bio materials · 17 Jun 2026 PMID 42306921
- Melatonin alleviates retrieval-induced forgetting deficits in acute sleep deprivation mice. Behavioural brain research · 6 Jun 2026 PMID 42250732
- Melatonin and cardiovascular risk: an NHANES reality check after recent heart failure concerns. Open heart · 21 May 2026 PMID 42167796
By study type
Clinical trials (4)
- Melatonin to improve sleep in patients undergoing major surgery: protocol for a double-blind, randomised placebo-controlled trial (MELROSE). BMJ open · 29 Sept 2026 PMID 42810800
- Implementation and real-world effectiveness of a weighted blanket intervention and standard melatonin treatment for children with ADHD and sleep problems: protocol for a pragmatic longitudinal cohort study. BMC psychiatry · 26 Aug 2026 PMID 42642740
- MELODY trial: study protocol for a 12-week randomised controlled trial of adjunctive melatonin, digital cognitive behavioural therapy for insomnia or pill placebo to improve depressive symptoms in young adults with mood disorders. BMJ open · 24 Aug 2026 PMID 42637255
- Melatonin Impairs Glucose Tolerance, First-Phase Insulin Secretion, and Insulin Feedback Inhibition; Interaction With MTNR1B Diabetes Risk Variant. Diabetes care · 25 Jun 2026 PMID 42346809
Human data, design not indexed (1)
- Melatonin and cardiovascular risk: an NHANES reality check after recent heart failure concerns. Open heart · 21 May 2026 PMID 42167796
Preclinical: animal, cell and lab studies (16)
- Protective effects of melatonin against bisphenol A-mediated endometrial tumorigenesis: An experimental study targeting COX-2-dependent MMP-9 expression. Taiwanese journal of obstetrics & gynecology · 28 Oct 2026 PMID 42951462
- Melatonin suppresses astrocyte reactivity and Mitigates cognitive deficits induced by a high-carbohydrate, high-fat diet in rats. Molecular biology reports · 26 Oct 2026 PMID 42932041
- Pharmacological melatonin induces mitochondrial dysfunction and alters extracellular nucleotide metabolism and CD39/CD73 expression in human melanoma cells. Purinergic signalling · 20 Oct 2026 PMID 42900413
- Melatonin ameliorates diabetic retinopathy by inhibiting PANoptosis via the LncSNHG5/miR-26a-5p/Hippo signaling axis. Journal of pharmacological sciences · 29 Sept 2026 PMID 42810779
- Melatonin-loaded nanoparticles reduce cisplatin-induced oxidative stress and lymphopenia: An experimental study in rats. Biochemical and biophysical research communications · 12 Sept 2026 PMID 42731366
- Melatonin@Exosome hydrogel composed of chitosan and hyaluronic acid: A promising dressing for wound healing based on exosome therapy. International journal of pharmaceutics · 7 Sept 2026 PMID 42705560
- Melatonin attenuates ferroptosis-associated injury through modulation of the thioredoxin-interacting protein/thioredoxin-1/glutathione peroxidase 4 pathway after neonatal hypoxic ischemic brain damage. Neuroreport · 3 Sept 2026 PMID 42689393
- A gelatin methacryloyl (GelMA)-based biomimetic melatonin/vascular endothelial growth factor-encoding plasmid (pVEGF) nerve conduit regulates the early redox-angiogenic microenvironment for long-gap peripheral nerve repair. International journal of biological macromolecules · 22 Aug 2026 PMID 42632501
- Oral administration of melatonin modulates macrophage polarization via modulating the Vegf signaling pathway and ameliorates Alzheimer's disease in APP/PS1 mice. Brain research bulletin · 17 Aug 2026 PMID 42607896
- Melatonin Ameliorates Neuropathic Pain in Mice by Regulating Pyroptosis Through Gut Microbiota-Mediated Linoleic Acid. Molecular neurobiology · 15 Aug 2026 PMID 42603252
- Multifunctional dual drug-loaded Gel-Alg/MINO/MEL composite hydrogel for combating three-dimensional multi-species biofilm and experimental periodontitis treatment. Clinical oral investigations · 6 Aug 2026 PMID 42560526
- Melatonin Modulates Behavioral and Physiological Responses in a Concentration-dependent Manner in a Pilocarpine-induced Seizure-like Model Using Zebrafish Larvae. Neurotoxicity research · 23 Jul 2026 PMID 42493757
- The protective role of melatonin on the brain in a rat model of Alzheimer's disease. Metabolic brain disease · 1 Jul 2026 PMID 42384283
- Oxidative degradation of melatonin in solution and solid-state pharmaceutical blends: HPLC-HRMS/MS degradant characterization, metal-mediated acceleration and EDTA mitigation. Journal of pharmaceutical and biomedical analysis · 24 Jun 2026 PMID 42341649
- Dissolving Microneedles for Transdermal Delivery of Melatonin: Fabrication, Characterization, and In Vivo Pharmacokinetic Evaluation in Mice. ACS applied bio materials · 17 Jun 2026 PMID 42306921
- Melatonin alleviates retrieval-induced forgetting deficits in acute sleep deprivation mice. Behavioural brain research · 6 Jun 2026 PMID 42250732
Written from 21 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-08-28 by GPT. Drafted by language models from published abstracts; not medical advice.